Cytek Biosciences, Inc. (CTKB) Stock Price & Analysis
Cytek Biosciences, Inc. (CTKB) closed at USD 6.14 on Wednesday, October 28, 2026, up 2.68% on the day. The US market is currently closed (after-hours); this is not a live price.
The prior close was USD 5.98; the Oct 28, 2026 session ranged USD 5.95–6.32 on volume of 1,597,341 shares. Market capitalization is $798.10M, with a 52-week range of USD 3.31–6.32 (NMS). Source: Nexqual, retrieved October 28, 2026 at 21:32 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CTKB.md
Key facts (CTKB)
- Last four reported quarters (through Jun 30, 2026): revenue $207M, net income -$80.6M (-39.0% margin), free cash flow -$12.1M (SEC filings).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (3 analysts), mean target USD 6.17 (range 5–7.5).
- Total return with dividends: 1Y +53.1% vs S&P 500 +13.6%; 5Y -73.1% vs S&P 500 +79.8%.
- Next earnings: 2026-11-04, EPS estimate USD -0.07, revenue estimate $52.9M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CTKB)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $128M | $164M | $193M | $200M | $201M | $207M |
| Gross profit | $79.1M | $101M | $109M | $111M | $104M | — |
| Operating income | $9.2M | -$1.8M | -$27.8M | -$20.5M | -$40.4M | -$44.6M |
| Net income | $3.0M | $2.5M | -$12.1M | -$6.0M | -$66.5M | -$80.6M |
| EPS (diluted) | $0.00 | $0.02 | -$0.09 | — | — | — |
| Free cash flow | $266K | -$22.0M | $633K | $21.9M | -$8.8M | -$12.1M |
| Gross margin | 61.9% | 61.6% | 56.7% | 55.4% | 51.8% | — |
| Operating margin | 7.2% | -1.1% | -14.4% | -10.2% | -20.0% | -21.6% |
| Net margin | 2.4% | 1.5% | -6.3% | -3.0% | -33.0% | -39.0% |
| Revenue growth | +37.8% | +28.2% | +17.7% | +3.9% | +0.5% | — |
| Cash + short-term investments | $365M | $297M | $167M | $98.7M | $90.9M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (CTKB)
P/S 3.9x · P/B 2.5x · FCF yield -1.51% · Earnings yield -10.10% · Buyback yield (TTM) 0.01%
Analysts (CTKB)
Consensus Buy (mean 2.00 on a 1–5 scale), 3 analysts; mean target USD 6.17 (low 5, high 7.5).
Total return (dividends reinvested) (CTKB)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +53.1% | -73.1% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | +53.3% | -23.1% |
| Volatility (annualized) | 55.3% | 63.9% |
| Max drawdown | -42.9% (Nov 2025→May 2026) | -90.2% (Nov 2021→May 2025) |
CTKB earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.03 | −$0.02 | Miss −$0.01 | — |
| — | Quarter ended Mar 31, 2026 | −$0.10 | −$0.08 | Miss −25.0% | — |
| — | Quarter ended Dec 31, 2025 | −$0.29 | $0.02 | Miss −$0.31 | — |
| — | Quarter ended Sep 30, 2025 | $0.00 | $0.01 | Miss −$0.01 | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
CTKB recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Sep 29, 2026 | 8-K | Bylaws or fiscal-year change |
| Aug 24, 2026 | 8-K | Regulation FD disclosure; Other material event “On August 21, 2026, the Company announced that a jury in the United States District Court for the District of Delaware returned a verdict in the patent infringement action brought by Beckman Coulter, Inc. The jury found in the Company's favor on three of the four asserted patent claims, finding noninfringement and invalidity as to each of those three claims. With respect to one claim, the jury found no literal infringement but found infringement under the doctrine of equivalents. The jury awarded past damages…” |
| Aug 6, 2026 | Schedule 13G/A | Integrated Core Strategies (US) LLC, Millennium Management LLC: 7.2% of shares, passive 5%+ holder (amended) |
| Aug 5, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 5, 2026 | 8-K | Quarterly results |
| Aug 4, 2026 | Schedule 13G | Boston Partners: 5.9% of shares, passive 5%+ holder |
| Jul 15, 2026 | 8-K | Director or executive officer change, or pay arrangement “(e) As previously disclosed, Valerie Barnett's position as Chief Legal Officer and Corporate Secretary of Cytek Biosciences, Inc. (the "Company") terminated on June 29, 2026. On July 9, 2026 (the "Separation Date"), the Company and Ms. Barnett entered into a severance agreement and release of all claims (the "Severance Agreement") pursuant to which Ms. Barnett provided the Company with a release and waiver of claims. In accordance with the Severance Agreement, the Company agreed to pay Ms. Barnett: (i) a one-time…” |
| Jul 8, 2026 | Schedule 13G/A | BlackRock, Inc.: 7.2% of shares, passive 5%+ holder (amended) |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
CTKB revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Product | $32.6M | 67.6% | +3.6% |
| Service | $15.6M | 32.4% | +9.8% |
| Total revenue | $48.1M | 100% | — |
CTKB revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $28.2M | 58.6% | +18.1% |
| EMEA | $11.3M | 23.5% | -8.2% |
| APAC | $7.9M | 16.4% | +0.6% |
| China | $4.8M | 10.0% | — |
| Other | $701,000 | 1.5% | -54.2% |
| Total revenue | $48.1M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
CTKB suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Coherent NA | “Pursuant to the Coherent Agreement, Coherent has agreed to sell and supply to us, Cytek Wuxi, and Cytek Singapore, on a non-exclusive basis, laser products manufactured by Coherent.” |
| Partner | Biotium | “On September 1, 2020, we entered into a Supply and License Agreement with Biotium, Inc. ("Biotium") pursuant to which Biotium agreed to supply, and we obtained a worldwide, non-exclusive license to market and resell to our customers and distributors, certain Biotium products to conjugate proteins and/or antibodies and to use such conjugates as a component in our cFluor reagent products, for research and analyte sp…” |
| Partner | Biosciences | “On January 6, 2025, Cytek (Shanghai) Biosciences Co., Ltd. signed a maximum credit agreement with the Bank of Ningbo for 10 million Chinese renminbi (approximately US $1.4 million).” |
| Partner | China Construction Bank | “On February 9, 2026, Cytek Wuxi entered into a one-year loan agreement with China Construction Bank Corporation, Wuxi Branch for 15 million Chinese renminbi (approximately US $2.2 million) at a fixed interest rate of 2.5%, with interest payable monthly.” |
| Competitor | Sony (SONY) | “Our direct competitors include Agilent Technologies, Beckman Coulter (Danaher Corporation), Bio-Rad Laboratories, Standard BioTools, Miltenyi Biotec, Sony Biotechnology (Sony Corporation), Thermo Fisher Scientific and Waters Corporation.” |
| Competitor | Thermo Fisher (TMO) | “Our competitors include Agilent Technologies, Beckman Coulter (Danaher Corporation), Bio-Rad Laboratories, Standard BioTools Inc., Miltenyi Biotec, Sony Biotechnology (Sony Corporation), Thermo Fisher Scientific, and Waters Corporation.” |
Quoted from the company's 10-K filed Feb 26, 2026.
CTKB company outlook (results filed Aug 5, 2026)
- “Cytek Biosciences is updating its revenue outlook for the full year 2026 to be in the range of $207 million to $212 million, raising the midpoint by $1 million, assuming no change in current foreign currency exchange rates.”
Quoted word-for-word from the SEC 8-K results press release.
CTKB analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.07 | $-0.06 | −$0.01 | $52.9M | 2 |
| Next quarter (ends Dec 2026) | $-0.02 | $-0.03 | +$0.01 | $63.6M | 2 |
| Current fiscal year (ends Dec 2026) | $-0.34 | $-0.35 | +$0.01 | $209.2M | 3 |
| Next fiscal year (ends Dec 2027) | $-0.25 | $-0.27 | +$0.01 | $222.8M | 3 |
Key Statistics (as of October 28, 2026 at 21:32 UTC)
| Price | USD 6.14 |
|---|---|
| Change | ▲ 2.68% (up) |
| Previous Close | USD 5.98 |
| Open | USD 5.95 |
| Day Range | USD 5.95 – 6.32 |
| 52-Week Range | USD 3.31 – 6.32 |
| Volume | 1,597,341 shares |
| Market Cap | $798.10M |
| Exchange | NMS |
Technical Analysis (CTKB)
Nexqual's technical model rates CTKB "BUY" based on 5 bullish and 3 bearish signals across 127 daily candles, as of October 28, 2026 at 21:32 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 72.98 (overbought) |
| vs SMA50 | Above (USD 5.22) |
| MACD | 0.16 (positive) |
Analyst Ratings (CTKB)
Wall Street analysts rate CTKB "Buy" based on 3 analysts, with a mean price target of USD 6.17 (range USD 5–7.5), per Nexqual as of October 28, 2026 at 21:32 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 6.17 |
| High Target | USD 7.5 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 2 / 1 / 0 |
Earnings (CTKB)
| Next Earnings Date | 2026-11-04 |
|---|---|
| Revenue Estimate | $52.95M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.03 vs est -0.02 ▼ miss |
| 2026-03-31 | USD -0.1 vs est -0.08 ▼ miss |
| 2025-12-31 | USD -0.29 vs est 0.02 ▼ miss |
| 2025-09-30 | USD -0 vs est 0.01 ▼ miss |
Source: Nexqual, October 28, 2026 at 21:32 UTC.
Financials & Fundamentals (CTKB)
| Total Revenue | $206.71M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +5.60% |
| Gross Margin | +51.88% |
| Operating Margin | -29.50% |
| Profit Margin | -38.98% |
| ROE | -23.04% |
| Debt / Equity | 0.08 |
| Current Ratio | 4.48 |
| Total Cash | $262.00M |
| Total Debt | $26.46M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$12.08M (-5.8% of revenue) |
Source: Nexqual, October 28, 2026 at 21:32 UTC.
Financial Health Score (CTKB)
Nexqual rates Cytek Biosciences, Inc.'s overall financial health "Mixed" across five dimensions, as of October 28, 2026 at 21:32 UTC.
| Growth | Mixed — Revenue +0.5% YoY (annual), slow |
|---|---|
| Profitability | Mixed — Gross margin 53%, operating -22% (last 4 quarters to Jun 2026, SEC) |
| Balance Sheet | Strong — $262M cash vs $26M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$12M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -25%, ROA -18.0% (last 4 quarters, SEC) |
Ownership (CTKB)
| Insider Ownership | +8.47% |
|---|---|
| Institutional Ownership | +62.85% |
| Shares Outstanding | 129.98M |
| Float | 102.94M |
| Short % of Float | +4.29% |
Source: Nexqual, October 28, 2026 at 21:32 UTC.
Leadership (CTKB)
Cytek Biosciences, Inc. is led by Wenbin Jiang, President, CEO & Chairman of the Board, per Nexqual as of October 28, 2026 at 21:32 UTC.
| President, CEO & Chairman of the Board | Wenbin Jiang |
|---|---|
| Chief Financial Officer | William D. McCombe |
| CTO & Director | Ming Yan |
Major Backers & Investors (CTKB)
Notable institutional backers of Cytek Biosciences, Inc. include Millennium Management, Boston Partners, HHLR Advisors, LTD, according to Nexqual as of October 28, 2026 at 21:32 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Millennium Management | 7.18% |
| Boston Partners | 5.89% |
| HHLR Advisors, LTD | 5.12% |
| Topline Capital Management, LLC | 4.83% |
| Trust for Professional Managers-Column Small Cap Select Fund | 1.99% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 7.37% |
| Vanguard Group | 3.8% |
| Geode Capital | 2.35% |
| Dimensional Fund Advisors | 2.01% |
| State Street | 1.97% |
Source: Nexqual, October 28, 2026 at 21:32 UTC.
From Cytek Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Each system is supported by our highly intuitive, proprietary embedded SpectroFlo® software, our reagents, and our service offerings to provide a comprehensive, end-to-end platform of solutions for our customers.
- Our proprietary tools and the intuitive functionality of our proprietary SpectroFlo software coupled with a user-friendly interface allow for enhanced ease-of-use and minimal operator training.
- Our proprietary SpectroFlo software is integrated into our systems and is unique in that it offers intuitive workflows for handling full spectrum flow cytometry data, from quality control to data acquisition and analysis.
- The DxP Athena system incorporates technology with efficient photomultiplier tubes to enable high sensitivity and high resolution and our proprietary QbSure software to ensure optimal daily instrument performance.
Partnerships
- On October 6, 2020, we entered into a Settlement, License and Equity Issuance Agreement with BD pursuant to which we and BD agreed to a mutual release of all claims against each other as of the date thereof (the "BD Agreement").
- Our Panel Builder tool combines all the features of the Full Spectrum Viewer with additional tools for panel design and collaboration in a simple and organized interface.
Legal & Regulatory Risks (Item 1A, quoted)
- Our products may become subject to more onerous regulation by the FDA or other regulatory agencies in the future, which could increase our costs and delay or prevent sales of our products or commercialization of new products and product enhancements, thereby materially and adversely affecting our business, financial condition, results of operations and prospects.
- We and our suppliers are subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and subject us to penalties if we fail to comply with applicable regulatory requirements.
- The misuse or off-label use of our products may harm our reputation in the marketplace, or result in injuries that lead to product liability suits, which could be costly to our business. Moreover, we could be subject to FDA sanctions if we are deemed to have engaged in off-label promotion.
- We are subject to U.S. and certain foreign anti-corruption and anti-money laundering laws and regulations. We can face criminal liability and other serious consequences for violations, which can harm our business.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ATEC | Alphatec Holdings, Inc. | USD 11.45 | ▲ 5.34% |
| INSP | Inspire Medical Systems, Inc. | USD 70.97 | ▼ 0.46% |
| ESTA | Establishment Labs Holdings Inc | USD 68.97 | ▲ 3.02% |
| BFLY | Butterfly Network, Inc. | USD 7.81 | ▲ 5.83% |
| UFPT | UFP Technologies, Inc. | USD 286 | ▼ 3% |
| TMDX | TransMedics Group, Inc. | USD 66.9 | ▼ 4.06% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 28, 2026 at 21:32 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt